NewLink Genetics Corporation (NASDAQ:NLNK) had its price target boosted by equities researchers at Stifel Nicolaus from $14.00 to $29.00 in a research note issued to investors on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 93.20% from the company’s current price.

A number of other equities analysts have also recently issued reports on NLNK. Jefferies Group LLC reissued a “hold” rating and issued a $18.00 target price on shares of NewLink Genetics Corporation in a report on Monday, May 15th. ValuEngine raised shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Cantor Fitzgerald set a $32.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Sunday, June 4th. Robert W. Baird reissued an “outperform” rating and issued a $25.00 target price on shares of NewLink Genetics Corporation in a report on Monday, June 5th. Finally, Zacks Investment Research raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. NewLink Genetics Corporation presently has a consensus rating of “Buy” and a consensus target price of $24.17.

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) opened at 15.01 on Monday. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17. The firm’s 50-day moving average price is $7.78 and its 200 day moving average price is $12.83. The stock’s market capitalization is $441.61 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The firm had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. Analysts expect that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/13/stifel-nicolaus-increases-newlink-genetics-corporation-nlnk-price-target-to-29-00.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of NewLink Genetics Corporation by 5.6% during the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock valued at $23,134,000 after buying an additional 51,013 shares during the last quarter. Columbus Circle Investors raised its holdings in shares of NewLink Genetics Corporation by 72.5% during the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock valued at $4,349,000 after buying an additional 248,724 shares during the last quarter. State Street Corp raised its holdings in shares of NewLink Genetics Corporation by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after buying an additional 4,630 shares during the last quarter. Northern Trust Corp raised its holdings in shares of NewLink Genetics Corporation by 4.0% during the second quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock valued at $2,195,000 after buying an additional 11,532 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new stake in shares of NewLink Genetics Corporation during the first quarter valued at approximately $5,127,000. 54.78% of the stock is currently owned by institutional investors.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.